-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Dow Jones·08/04/2026 11:00:00

Please log in to view news